Enhancing CHK1 inhibitor lethality in glioblastoma

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009; 18:1061 - 83; http://dx.doi.org/10.1517/13543780903052764; PMID: 19555299
   PubMed Web of Science ®Google Scholar
• Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, et al. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 2009; 13:701 - 18; http://dx.doi.org/10.1517/14728220902942348; PMID: 19409033
   PubMed Web of Science ®Google Scholar
• Gömöri E, Halbauer JD, Kasza G, Varga D, Horvath Z, Komoly S. Glioblastoma multiforme with an unusual location and clinical course. Clin Neuropathol 2009; 28:165 - 7; PMID: 19537131
   PubMed Web of Science ®Google Scholar
• Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 2000; 26:397 - 409; http://dx.doi.org/10.1053/ctrv.2000.0191; PMID: 11139371
   PubMed Web of Science ®Google Scholar
• Eley KW, Benedict SH, Chung TD, Kavanagh BD, Broaddus WC, Schmidt-Ullrich RK, et al. The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation. Int J Radiat Oncol Biol Phys 2002; 54:542 - 50; http://dx.doi.org/10.1016/S0360-3016(02)02983-8; PMID: 12243834
   PubMed Web of Science ®Google Scholar
• Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17:88 - 96; http://dx.doi.org/10.1016/j.molmed.2010.10.009; PMID: 21087899
   PubMed Web of Science ®Google Scholar
• Ashwell S, Zabludoff S. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008; 14:4032 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-07-5138; PMID: 18593978
   PubMed Web of Science ®Google Scholar
• Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 2011; 11:133 - 40; http://dx.doi.org/10.1124/mi.11.2.11; PMID: 21540473
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood 2011; 118:5189 - 200; http://dx.doi.org/10.1182/blood-2011-02-339432; PMID: 21911831
   PubMed Web of Science ®Google Scholar
• Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, et al. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. Cancer Biol Ther 2011; 12:215 - 28; http://dx.doi.org/10.4161/cbt.12.3.16218; PMID: 21642769
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, et al. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011; 117:1947 - 57; http://dx.doi.org/10.1182/blood-2010-06-291146; PMID: 21148814
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008; 112:2439 - 49; http://dx.doi.org/10.1182/blood-2008-05-159392; PMID: 18614762
   PubMed Web of Science ®Google Scholar
• Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 2005; 4:457 - 70; PMID: 15767555
   PubMed Web of Science ®Google Scholar
• Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001; 61:5106 - 15; PMID: 11431348
   PubMed Web of Science ®Google Scholar
• Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002; 100:3333 - 43; http://dx.doi.org/10.1182/blood-2002-03-0940; PMID: 12384435
   PubMed Web of Science ®Google Scholar
• Mitchell C, Park M, Eulitt P, Yang C, Yacoub A, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Mol Pharmacol 2010; 78:909 - 17; http://dx.doi.org/10.1124/mol.110.067199; PMID: 20696794
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther 2004; 3:739 - 51; http://dx.doi.org/10.4161/cbt.3.8.968; PMID: 15197348
   PubMed Web of Science ®Google Scholar
• Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther 2010; 18:1130 - 42; http://dx.doi.org/10.1038/mt.2010.29; PMID: 20179672
   PubMed Web of Science ®Google Scholar
• Yacoub A, Gupta P, Park MA, Rhamani M, Hamed H, Hanna D, et al. Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Mol Cancer Ther 2008; 7:314 - 29; http://dx.doi.org/10.1158/1535-7163.MCT-07-2150; PMID: 18281516
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mitchell C, Lebedeva IV, Sarkar D, Su ZZ, McKinstry R, et al. mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling. Cancer Biol Ther 2003; 2:347 - 53; http://dx.doi.org/10.4161/cbt.2.4.422; PMID: 14508103
   PubMed Web of Science ®Google Scholar
• Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008; 7:3519 - 26; http://dx.doi.org/10.1158/1535-7163.MCT-08-0138; PMID: 19001435
   PubMed Web of Science ®Google Scholar
• Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 2010; 8:35 - 45; http://dx.doi.org/10.1158/1541-7786.MCR-09-0220; PMID: 20053726
   PubMed Web of Science ®Google Scholar
• Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther 2008; 7:297 - 313; http://dx.doi.org/10.1158/1535-7163.MCT-07-2166; PMID: 18281515
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al, Association of French-Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356:1527 - 35; http://dx.doi.org/10.1056/NEJMoa065901; PMID: 17429084
   PubMed Web of Science ®Google Scholar
• Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, et al. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Phys Med Biol 2010; 55:3271 - 85; http://dx.doi.org/10.1088/0031-9155/55/12/001; PMID: 20484781
   PubMed Web of Science ®Google Scholar
• Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther 2008; 7:616 - 29; http://dx.doi.org/10.1158/1535-7163.MCT-07-2376; PMID: 18347148
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P, et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood 2007; 110:2092 - 101; http://dx.doi.org/10.1182/blood-2007-04-083204; PMID: 17540843
   PubMed Web of Science ®Google Scholar
• Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 2010; 10:903 - 17; http://dx.doi.org/10.4161/cbt.10.9.13273; PMID: 20855960
   PubMed Web of Science ®Google Scholar
• Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 2009; 76:327 - 41; http://dx.doi.org/10.1124/mol.109.056309; PMID: 19483105
   PubMed Web of Science ®Google Scholar
• Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223:14 - 26; PMID: 20049846
   PubMed Web of Science ®Google Scholar
• McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, et al. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol Ther 2002; 1:243 - 53; PMID: 12432271
   PubMed Web of Science ®Google Scholar
• Pei XY, Li W, Dai Y, Dent P, Grant S. Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. Mol Pharmacol 2006; 70:1965 - 73; http://dx.doi.org/10.1124/mol.106.028373; PMID: 16940414
   PubMed Web of Science ®Google Scholar
• Mogila V, Xia F, Li WX. An intrinsic cell cycle checkpoint pathway mediated by MEK and ERK in Drosophila. Dev Cell 2006; 11:575 - 82; http://dx.doi.org/10.1016/j.devcel.2006.08.010; PMID: 17011495
   PubMed Web of Science ®Google Scholar
• Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421 - 9; http://dx.doi.org/10.1016/S1535-6108(03)00110-7; PMID: 12781359
   PubMed Web of Science ®Google Scholar
• Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 2006; 66:11576 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-06-3095; PMID: 17178848
   PubMed Web of Science ®Google Scholar
• Zhuang J, Zhang J, Willers H, Wang H, Chung JH, van Gent DC, et al. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res 2006; 66:1401 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-3278; PMID: 16452195
   PubMed Web of Science ®Google Scholar
• Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177 - 96; http://dx.doi.org/10.1101/gad.914401; PMID: 11544175
   PubMed Web of Science ®Google Scholar
• Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 2002; 99:14795 - 800; http://dx.doi.org/10.1073/pnas.182557299; PMID: 12399544
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006; 5:1983 - 8; http://dx.doi.org/10.4161/cc.5.17.3184; PMID: 16931916
   PubMed Web of Science ®Google Scholar
• Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 2004; 3:1177 - 81; http://dx.doi.org/10.4161/cc.3.9.1080; PMID: 15326376
   PubMed Web of Science ®Google Scholar
• Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005; 4:131 - 9; http://dx.doi.org/10.4161/cc.4.1.1299; PMID: 15539958
   PubMed Web of Science ®Google Scholar
• Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 2007; 6:935 - 44; http://dx.doi.org/10.1158/1535-7163.MCT-06-0567; PMID: 17363488
   PubMed Web of Science ®Google Scholar
• Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 2000; 275:322 - 7; http://dx.doi.org/10.1074/jbc.275.1.322; PMID: 10617621
   PubMed Web of Science ®Google Scholar
• Sampath D, Plunkett W. The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Res 2000; 60:6408 - 15; PMID: 11103806
   PubMed Web of Science ®Google Scholar
• Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, et al. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995; 376:785 - 8; http://dx.doi.org/10.1038/376785a0; PMID: 7651539
   PubMed Web of Science ®Google Scholar